Saxena U, Auerbach B J, Ferguson E, Wölle J, Marcel Y L, Weisgraber K H, Hegele R A, Bisgaier C L
Department of Atherosclerosis Therapeutics, Parke-Davis Pharmaceutical Research, Ann Arbor, MI 48105, USA.
Arterioscler Thromb Vasc Biol. 1995 Aug;15(8):1240-7. doi: 10.1161/01.atv.15.8.1240.
Lipoprotein accumulation in the subendothelial matrix is an important step in atherogenesis. We have previously shown that addition of lipoprotein lipase (LPL) markedly increased binding of apolipoprotein B (apoB)-containing lipoproteins to an endothelial cell-derived matrix, and this enhanced lipoprotein binding was inhibited by apoE. In the present studies we examined the role of various regions of apoB in the binding of LDL to LPL-containing endothelial cell matrix and the ability of various apoE domains to decrease lipoprotein retention. We studied three apoB epitope-specific monoclonal antibodies for their ability to block the binding of 125I-LDL to LPL-containing matrix. Of these, monoclonal antibody 4G3, which recognizes an arginine-containing epitope in apoB, was the most effective in reducing LDL binding. Chemical modification of LDL apoB lysines or arginines markedly reduced the ability of the lipoprotein to block the binding of 125I-LDL to LPL-containing matrix, suggesting that apoB positively charged amino acids are involved in the interaction. Furthermore, polyarginine or polylysine markedly decreased 125I-LDL binding to LPL-containing matrix, whereas polyleucine was ineffective. These data suggest that apoB positively charged regions are important in LDL binding. To explore the role of charge modifications on apoE by single arginine-cysteine interchanges, we examined the effects of the three major human apoE isoforms (apoE2, apoE3, and apoE4). ApoE3 was the most effective in decreasing 125I-LDL retention, followed by apoE4; apoE2 was the least effective. Similarly, apoE2-containing HDL was much less effective than apoE3-containing HDL in decreasing 125I-LDL retention.(ABSTRACT TRUNCATED AT 250 WORDS)
脂蛋白在内皮下基质中的蓄积是动脉粥样硬化形成过程中的一个重要步骤。我们之前已经表明,添加脂蛋白脂肪酶(LPL)可显著增加含载脂蛋白B(apoB)的脂蛋白与内皮细胞衍生基质的结合,而这种增强的脂蛋白结合被apoE抑制。在本研究中,我们研究了apoB不同区域在低密度脂蛋白(LDL)与含LPL的内皮细胞基质结合中的作用,以及各种apoE结构域降低脂蛋白潴留的能力。我们研究了三种apoB表位特异性单克隆抗体阻断125I-LDL与含LPL基质结合的能力。其中,识别apoB中含精氨酸表位的单克隆抗体4G3在减少LDL结合方面最有效。对LDL的apoB赖氨酸或精氨酸进行化学修饰可显著降低该脂蛋白阻断125I-LDL与含LPL基质结合的能力,这表明apoB带正电荷的氨基酸参与了这种相互作用。此外,聚精氨酸或聚赖氨酸可显著降低125I-LDL与含LPL基质的结合,而聚亮氨酸则无效。这些数据表明apoB带正电荷区域在LDL结合中很重要。为了通过单个精氨酸-半胱氨酸交换探索电荷修饰对apoE的作用,我们研究了三种主要的人类apoE异构体(apoE2、apoE3和apoE4)的作用。apoE3在降低125I-LDL潴留方面最有效,其次是apoE4;apoE2最无效。同样,含apoE2的高密度脂蛋白(HDL)在降低125I-LDL潴留方面比含apoE3的HDL效果差得多。(摘要截短于250字)